Wird geladen...
Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review
Ruxolitinib, a Janus kinase inhibitor, considerably improves symptoms of patients with polycythemia vera and primary or secondary myelofibrosis. However, its association with the development of infectious complications is a concern. Herein, we report the case of an 80-year-old man with primary myelo...
Gespeichert in:
| Veröffentlicht in: | IDCases |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elsevier
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7332526/ https://ncbi.nlm.nih.gov/pubmed/32642438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.idcr.2020.e00892 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|